Implications for Axillary Radiation Following Review of the ACOSOG Z11 Trial
Judy C. Boughey, MD, associate professor of surgery, director, Breast Surgical Oncology Training Program, Mayo Clinic, discusses implications for axillary radiation following review of the ACOSOG Z11 trial.
Judy C. Boughey, MD, associate professor of surgery, director, Breast Surgical Oncology Training Program, Mayo Clinic, discusses implications for axillary radiation following review of the ACOSOG Z11 trial.
Clinical Pearls:
- Data from the study suggested that the patients should not receive radiation directed towards the axilla, but no data was collected on how the patients were treated.
- A recent study in which ACOSOG researchers looked at radiation reports showed that the majority of patients were treated with standard tangents and not with definitive radiation to the axilla. In the study, 89% of patients received radiation to the breast and about 15% had definitive radiation to the supraclavicular area.
- A small subset of 200 patients from the study showed no difference in the radiation field planning between the group that was randomized to sentinel node only and the group that underwent axillary lymph node dissection.
- While this information is encouraging, it is too small of a group to provide a definitive answer.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
